Evidence map›Paper›PMID 41245659›Full record

ArticleJournal of pharmaceutical analysis2025

Tumor cells targetable graphene oxide doped microneedle for synergistic photothermal-chemotherapy treatment of melanoma.

Zhiqiang Zhang, Junfang Ke, Yuxin Dai, Chenxi Fang, Yunfeng Dai, Chen Wang, Meitao Duan, Jungang Ren, Ming Chen, Chen Wang

Abstract read
In one paragraph

Article in Journal of pharmaceutical analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhiqiang ZhangSchool of Pharmacy, Xiamen Medical College, Xiamen, Fujian, 361023, China.
Junfang KeSchool of Pharmacy, Xiamen Medical College, Xiamen, Fujian, 361023, China.
Yuxin DaiSchool of Pharmacy, Xiamen Medical College, Xiamen, Fujian, 361023, China.
Chenxi FangSchool of Pharmacy, Xiamen Medical College, Xiamen, Fujian, 361023, China.
Yunfeng DaiSchool of Pharmacy, Xiamen Medical College, Xiamen, Fujian, 361023, China.
Chen WangSchool of Pharmacy, Xiamen Medical College, Xiamen, Fujian, 361023, China.
Meitao DuanSchool of Pharmacy, Xiamen Medical College, Xiamen, Fujian, 361023, China.
Jungang RenSchool of Pharmacy, Xiamen Medical College, Xiamen, Fujian, 361023, China.
Ming ChenSchool of Pharmacy, Xiamen Medical College, Xiamen, Fujian, 361023, China.
Chen WangSchool of Pharmacy, Xiamen Medical College, Xiamen, Fujian, 361023, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is characterized by high malignancy, ranking the third among skin malignancies, and is associated with lack of specific treatment options and poor prognosis. Therefore, the development of effective therapies for melanoma is imperative. A critical challenge in addressing subcutaneous disease lies in overcoming the skin barrier. In this study, we engineered a microneedle (MN) system that integrates chemotherapy, photothermal therapy (PTT), and targeted therapy to enhance anti-tumor efficacy while effectively penetrating the skin barrier.

Indexed as

MelanomaMicroneedlePhotothermal therapy

Identifiers

PMID41245659
PMCPMC12616066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.